Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIMI Regulatory News (IMI)

Share Price Information for IMI (IMI)

Share Price is delayed by 15 minutes
Get Live Data
2,818.00    -10.00 (-0.35%)
Bid:
2,818.00
Ask:
2,820.00
Spread: 2.00 (0.071%)
Market Cap: £6.70b
IMI Live PriceLast checked at - London Stock Exchange

Intraday IMI Share Chart

Trading Update

7 Nov 2024 07:00

RNS Number : 2337L
IMI PLC
07 November 2024
 

7 November 2024

 

Resilient quarterly sales with continued margin improvement

Full year adjusted EPS guidance reconfirmed

Acquisition of leading sensor technology business

 

IMI plc ("IMI" or the "Group"), the specialist engineering company, issues the following trading update which covers results for the third quarter from 1 July to 30 September 2024.

 

Roy Twite, Chief Executive, commented:

 

"We continue to expect good organic growth in 2024, having delivered a resilient performance in the third quarter. Organic revenue was up 1%, with good growth in our Automation platform partly offset by a weaker performance in Life Technology, as expected. Process Automation, our largest business sector, had another excellent quarter with continued momentum across our energy end markets and strong order intake.

 

Margins in both platforms were higher in the quarter, benefitting from our significant aftermarket exposure, continued delivery of high value-added solutions for our customers and further efficiency gains.

 

We are reconfirming guidance. We continue to expect that full year adjusted basic earnings per share will be between 120p - 126p, despite seeing some additional foreign exchange headwinds. This guidance represents another year of around 10% adjusted organic operating profit growth."

 

Resilient third quarter performance

 

Third quarter organic revenue was 1% higher than the same period last year, with the Group now 3% higher year to date. Statutory revenue in the quarter was 3% lower than last year, reflecting the foreign currency movements seen in the period.

 

Our complexity reduction initiatives remain on track to deliver £15m of incremental benefits for the full year and £7m in 2025. The programme will complete this year, although IMI will continue identify and execute efficiencies within its operations. Future restructuring costs within our current business will be taken into underlying operating profit.

 

Sector performance in line with expectations

 

Automation

 

Automation (62% of 2023 sales) delivered a strong performance, with revenue in the quarter up 4% organically, and 7% year to date.

 

· Process Automation (37% of 2023 sales) had another excellent quarter as we saw continued momentum across our energy end markets and further progress in the Aftermarket. Order intake in the third quarter was 14% higher organically and revenue was 9% higher than the same period last year on an organic basis. Book-to-bill is now at 1.15 over the last twelve months.

 

· Industrial Automation (25% of 2023 sales) third quarter organic revenue was 2% lower than the same period last year, a resilient performance despite mixed end markets.

 

Life Technology

 

As expected, Life Technology (38% of 2023 sales) revenue was down 5% organically in the third quarter, and 2% lower year to date.

 

· Climate Control (18% of 2023 sales) organic revenue in the third quarter was 4% higher than the same period last year as we saw continued good demand for our energy efficient products.

 

· Life Science and Fluid Control (12% of 2023 sales) organic revenue was down 10% in the third quarter reflecting the continued softness seen across the global life sciences device market.

 

· Transport (8% of 2023 sales) organic revenue was down 16% in the third quarter, as expected given the 20% organic growth delivered in the third quarter of 2023. Sector revenue is now 3% higher year to date.

 

Disciplined approach to capital allocation

 

IMI is a highly cash generative business with a clear and disciplined approach to capital allocation, prioritising investment that accelerates organic growth.

 

IMI will also pursue strategic acquisitions that strengthen its position in attractive, better world markets and deliver returns in line with its strict financial criteria. On 31 October 2024 IMI announced the acquisition of TWTG Group B.V. ("TWTG") for an enterprise value of €25m. TWTG is a leading innovator of smart connected asset monitoring solutions. The combination with IMI will create a significant opportunity to accelerate aftermarket growth in Process Automation.

 

In addition, reflecting its commitment to maintain an efficient balance sheet, IMI announced a £100m share buyback at the interim results in July 2024. The buyback was completed in October.

 

By deploying our growing free cash flow into organic growth opportunities, attractive acquisitions and share buybacks, IMI can continue its track record of compounding EPS growth.

 

Exchange rates

 

If exchange rates as at 1 November 2024 of US$1.29 and €1.19 remain constant for the remainder of the year it would negatively impact both revenue and adjusted operating profit by approximately 3% in the 2024 full year when compared to 2023.

 

Outlook

 

Based on current market conditions, we are reiterating our guidance that 2024 full year adjusted basic EPS will be between 120p - 126p.

 

Interim results

 

IMI will present its preliminary results announcement for the year ending 31 December 2024 on 28 February 2025.

 

Enquiries

 

Edward Hann

IMI

Tel: +44 (0)7977 354 810

Matt Denham

Headland

Tel: +44 (0)7551 825 496

 

A conference call for analysts and investors will be held at 08:00 GMT today to discuss this statement. To access the call, please register using the link:

 

https://www.netroadshow.com/events/login?show=7c005d8a&confId=72097

 

Notes

 

IMI plc is a FTSE100 global specialist engineering company that designs, manufactures and services highly engineered products to control the precise movement of fluids. Its innovative motion and flow control technologies, built around valves and actuators, enable vital sectors to become safer, more sustainable and more productive. IMI combines world class applications engineering expertise with a continued focus on customer satisfaction, market-led innovation and complexity reduction to solve its customers most acute engineering problems. IMI employs approximately 10,000 people, has manufacturing facilities in 18 countries and operates a global service network. The Company is listed on the London Stock Exchange. Further information is available at www.imiplc.com.

 

References to adjusted figures reflect figures as reported to management and do not include the impact of adjusting items. References to organic changes are on a constant currency basis and exclude disposals and acquisitions.

 

IMI plc is registered in England No. 714275. Its legal entity identifier ('LEI') number is 2138002W9Q21PF751R30.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUNSNRSWUARAA
Date   Source Headline
1st May 201511:19 amRNSTotal Voting Rights
17th Apr 20153:13 pmRNSDirector/PDMR Shareholding
15th Apr 201512:18 pmRNSDirector/PDMR Shareholding
1st Apr 20159:57 amRNSTotal Voting Rights
26th Mar 20153:49 pmRNSAnnual Financial Report
25th Mar 20153:22 pmRNSDirector/PDMR Shareholding
19th Mar 20152:47 pmRNSDirector/PDMR Shareholding
18th Mar 20157:00 amRNSChairman Appointment
11th Mar 20151:37 pmRNSDirector/PDMR Shareholding
9th Mar 201511:02 amRNSAppointment of Divisional Managing Director
6th Mar 20159:39 amRNSDirector Declaration
3rd Mar 20152:22 pmRNSDirector Declaration
2nd Mar 201511:25 amRNSTotal Voting Rights
27th Feb 20157:00 amRNSFinal Results
11th Feb 20152:19 pmRNSDirector/PDMR Shareholding
2nd Feb 201510:26 amRNSTotal Voting Rights
22nd Jan 20154:39 pmRNSHolding(s) in Company
14th Jan 20153:10 pmRNSDirector/PDMR Shareholding
6th Jan 201511:07 amRNSBlocklisting Interim Review
2nd Jan 20153:37 pmRNSCompletion of Bopp & Reuther acquisition
2nd Jan 201512:03 pmRNSTotal Voting Rights
17th Dec 20147:06 amRNSChairman announcement
10th Dec 20143:00 pmRNSDirector/PDMR Shareholding
1st Dec 201411:13 amRNSTotal Voting Rights
27th Nov 20144:10 pmRNSHolding(s) in Company
14th Nov 20147:00 amRNSAcquisition announcement
14th Nov 20147:00 amRNSInterim Management Statement
12th Nov 20142:00 pmRNSDirector/PDMR Shareholding
3rd Nov 201410:02 amRNSTotal Voting Rights
15th Oct 201412:39 pmRNSDirector/PDMR Shareholding
6th Oct 20144:52 pmRNSHolding(s) in Company
6th Oct 20141:00 pmRNSSale of non-core businesses
1st Oct 201410:31 amRNSDirectorate Change
1st Oct 20149:50 amRNSTotal Voting Rights
23rd Sep 20143:15 pmRNSDirector/PDMR Shareholding
23rd Sep 20147:00 amRNSFinance Director Succession
22nd Sep 20144:34 pmRNSDirector/PDMR Shareholding
10th Sep 20143:41 pmRNSDirector/PDMR Shareholding
1st Sep 201412:45 pmRNSTotal Voting Rights
13th Aug 20143:34 pmRNSDirector/PDMR Shareholding
4th Aug 20143:58 pmRNSDirector/PDMR Shareholding
1st Aug 201410:13 amRNSTotal Voting Rights
1st Aug 20147:00 amRNSHalf Yearly Report
9th Jul 20142:07 pmRNSDirector/PDMR Shareholding
2nd Jul 20141:58 pmRNSBlocklisting Interim Review
1st Jul 201410:46 amRNSTotal Voting Rights
17th Jun 20144:35 pmRNSHolding(s) in Company
11th Jun 20141:41 pmRNSDirector/PDMR Shareholding
11th Jun 20141:33 pmRNSDirector Declaration
2nd Jun 201411:09 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.